New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 3, 2012
14:44 EDTALRAlere rallies after disclosing deal with FDA, updating revenue view
Alere (ALR) is surging after the company disclosed earlier today that it had reached a deal with the FDA on final release specifications for its Alere Triage meter-based products. The new specifications will further align the product release specifications to the package insert, and, as expected, represents a further tightening of the release specifications for Alere's Triage products, the company said. The company believes that the new specifications will result in lower manufacturing yields, but it continued to expand its manufacturing capacity to address the expected lower yield rate. Alere announced that revenue from its Alere Triage Cardiac Panel products in the U.S. were about $6M in the third quarter, in-line with its previous guidance of $4M-$8M. The company projects a supply shortfall for its Cardiac Panel products during October but expects to be able to meet demand for its cardiac panel in the U.S. from November onwards, it said. Alere estimates that its revenue from the panels in the U.S. will be about $6M-$8M in the fourth quarter. Revenues from sales of the TOX product line in the U.S. came in at $7M for the third quarter of 2012. Alere expects revenue of approximately $4M-$5M from U.S. sales of the product in the fourth quarter. In mid-afternoon trading, Alere rose $1.60, or 8.25%, to $20.99.
News For ALR From The Last 14 Days
Check below for free stories on ALR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
08:54 EDTALRAlere CEO takeover attempt lacks financing details, says Raymond James
Subscribe for More Information
07:31 EDTALREuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:18 EDTALRAlere worth $45-$50 to strategic buyer, says Canaccord
Canaccord noted the former Chairman and CEO of Alere revealed a proposed buyout of $46 per share. The firm feels the filing indicates genuine interest and believes the company may be worth $45-$50 to a strategic buyer. Canaccord raised its price target to $46 to match the offer and reiterates its Buy rating on the shares.
September 15, 2014
19:32 EDTALRAlere responds to letter from former executives
Subscribe for More Information
12:31 EDTALROn The Fly: Midday Wrap
Subscribe for More Information
09:15 EDTALRRon Zwanziger plans to offer $46 per share to aquire Alere
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use